MiNK Therapeutics Files 8-K with Corporate Updates
Ticker: INKT · Form: 8-K · Filed: Jan 21, 2025 · CIK: 1840229
Sentiment: neutral
Topics: corporate-governance, filing-update
TL;DR
MiNK Therapeutics filed an 8-K on Jan 17, 2025, reporting corporate updates and formerly AgenTus Therapeutics.
AI Summary
MiNK Therapeutics, Inc. filed an 8-K on January 21, 2025, reporting events as of January 17, 2025. The filing indicates amendments to articles of incorporation or bylaws, submission of matters to a vote of security holders, and financial statements/exhibits. The company was formerly known as AgenTus Therapeutics, Inc., with a name change effective January 12, 2021.
Why It Matters
This 8-K filing signals potential changes in MiNK Therapeutics' corporate structure or governance, which could impact investors and stakeholders.
Risk Assessment
Risk Level: low — The filing is a routine corporate disclosure and does not appear to contain significant negative news.
Key Players & Entities
- MiNK Therapeutics, Inc. (company) — Registrant
- AgenTus Therapeutics, Inc. (company) — Former company name
- January 17, 2025 (date) — Earliest event reported date
- January 21, 2025 (date) — Filing date
- Delaware (jurisdiction) — State of incorporation
- New York (location) — Principal executive office city
FAQ
What specific amendments were made to MiNK Therapeutics' articles of incorporation or bylaws?
The filing indicates that amendments were made, but the specific details of these amendments are not provided in the excerpt.
What matters were submitted to a vote of security holders?
The filing states that matters were submitted to a vote of security holders, but the nature of these matters is not detailed in the provided text.
What financial statements and exhibits are included with this 8-K filing?
The filing lists 'Financial Statements and Exhibits' as an item information, but the specific content of these documents is not detailed in the excerpt.
When did MiNK Therapeutics officially change its name from AgenTus Therapeutics, Inc.?
The date of the name change from AgenTus Therapeutics, Inc. to MiNK Therapeutics, Inc. was January 12, 2021.
What is the principal executive office address for MiNK Therapeutics, Inc.?
The principal executive offices are located at 149 Fifth Avenue, Suite 500, New York, New York 10010.
Filing Stats: 709 words · 3 min read · ~2 pages · Grade level 10.7 · Accepted 2025-01-21 16:52:22
Key Financial Figures
- $0.00001 — ich registered Common Stock, par value $0.00001 per share INKT The Nasdaq Stock Mar
Filing Documents
- d926991d8k.htm (8-K) — 28KB
- d926991dex31.htm (EX-3.1) — 8KB
- 0001193125-25-009595.txt ( ) — 170KB
- inkt-20250117.xsd (EX-101.SCH) — 3KB
- inkt-20250117_lab.xml (EX-101.LAB) — 20KB
- inkt-20250117_pre.xml (EX-101.PRE) — 12KB
- d926991d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 21, 2025 By: /s/ Jennifer Buell, Ph.D. Jennifer Buell, Ph.D., President and CEO